The first successful case of ABO-incompatible living-donor lobar lung transplantation following desensitization therapy

被引：3

作者：

Nakajima, Daisuke ^{[1
]}

Yuasa, Itsuki ^{[1
]}

Kayawake, Hidenao ^{[1
]}

Tanaka, Satona ^{[1
]}

Yamada, Yoshito ^{[1
]}

Yutaka, Yojiro ^{[1
]}

Hamaji, Masatsugu ^{[1
]}

Ohsumi, Akihiro ^{[1
]}

Ikeda, Tadashi ^{[2
]}

Suga, Takenori ^{[3
]}

Baba, Shiro ^{[3
]}

Hiramatsu, Hidefumi ^{[3
]}

Date, Hiroshi ^{[1
]}

机构：

[1] Kyoto Univ, Grad Sch Med, Dept Thorac Surg, 54 Shogoin Kawahara Cho,Sakyo Ku, Kyoto 6068507, Japan

[2] Kyoto Univ, Grad Sch Med, Dept Cardiovasc Surg, Kyoto, Japan

[3] Kyoto Univ, Grad Sch Med, Dept Pediat, Kyoto, Japan

来源：

AMERICAN JOURNAL OF TRANSPLANTATION | 2023年 / 23卷 / 09期

关键词：

ABO-incompatible; living donor; lung transplantation; desensitization; rituximab; plasmapheresis; ANTIGEN-SPECIFIC IMMUNOADSORPTION; KIDNEY-TRANSPLANTATION; MANAGEMENT; RITUXIMAB;

D O I：

10.1016/j.ajt.2023.04.031

中图分类号：

R61 [外科手术学];

学科分类号：

摘要：

ABO-incompatible (ABO-I) living-donor lobar lung transplantation (LDLLT) was successfully performed in a 14-year-old girl who suffered from bronchiolitis obliterans due to graftversus-host disease following hematopoietic stem cell transplantation. In the ABO-I LDLLT procedure, the blood type O patient received a right lower lobe donated from her blood type B father and a left lower lobe donated from her blood type O mother. Desensitization therapy, using rituximab, immunosuppressants, and plasmapheresis, was implemented for 3 weeks prior to transplantation to reduce the production of anti-B antibodies in the recipient and prevent acute antibody-mediated rejection after ABO-I LDLLT.

引用

页码：1451 / 1454

页数：4

共 19 条

[1]

ALEXANDRE GPJ, 1987, TRANSPLANT P, V19, P4538

[2] Management of an ABO-incompatible lung transplant [J].